Absci Corporation

The move is getting stronger, with heavier trading behind it.

Absci at 99% of its 52-week range — AI drug-discovery biotech with director Pangalos buying $201K on May 13.

Absci Corporation is a clinical-stage AI drug-discovery biotech — uses generative AI to design novel antibodies and protein therapeutics, then validates them in vitro and in vivo before licensing to pharma partners. The setup is multi-layered. The stock is up 107% YTD and 158% over twelve months, sitting at the 99th percentile of its 52-week range. The most concrete insider signal in the recent window: director Menelas Pangalos bought $201K open-market on May 13 — the kind of conviction signal that doesn't come randomly for a stock at all-time highs. Q1 revenue fell 81.8% YoY to $215K at -14,347% operating margin — revenue is essentially noise on a quarter-to-quarter basis given the licensing-deal structure. At $1.14B market cap and 623x trailing sales the multiple is mechanically meaningless on the current run-rate; the multiple makes sense only against future AI-designed antibody licensing revenue. The 1.78x volume multiplier confirms breakout accumulation.